Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan vs CDK4/6 Inhibitors in ER+/HER2-low Metastatic Breast Cancer
NCT06585969Phase 3Withdrawn
- Sponsor
- Danish Breast Cancer Cooperative Group
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Danish Breast Cancer Cooperative Group. Planned start Jan 2026; status: withdrawn.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06585969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585969.